Lv1
40 积分 2023-08-04 加入
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
13小时前
待确认
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
13小时前
已完结
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
6个月前
已完结
GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts
6个月前
已关闭
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
6个月前
已完结
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study
6个月前
已完结
Can population differences in chemotherapy outcomes be inferred from differences in pharmacogenetic frequencies?
6个月前
已完结
Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian in Phase II and III Clinical Trials
6个月前
已完结
‘PARP’ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors
6个月前
已完结
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results
7个月前
已完结
皖公网安备34019202002308
